ResMed Inc.
RMD Healthcare Medical Instruments & Supplies
ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.
Follow RMD
ResMed Inc. (RMD) Return on invested capital
ResMed Inc.'s return on invested capital over the twelve months to 30 June 2026 was 21.4%. Over the past ten years it has ranged from 11.4% (fiscal 2019) to 21.9% (fiscal 2015); the current reading is higher than 92% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2026 | 21.4% | 1.93 |
| FY2025 | 19.5% | 3.95 |
| FY2024 | 15.5% | 2.24 |
| FY2023 | 13.3% | (2.97) |
| FY2022 | 16.2% | (1.24) |
| FY2021 | 17.5% | 1.65 |
| FY2020 | 15.8% | 4.45 |
| FY2019 | 11.4% | (4.45) |
| FY2018 | 15.8% | 3.82 |
| FY2017 | 12.0% | (2.60) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| RMD ResMed Inc. | 21.4% |
| MDLN Medline Inc. compare | 19.9% |
| WST West Pharmaceutical Services, Inc. compare | 15.4% |
| SOLV Solventum Corporation compare | 13.4% |
| BDX Becton, Dickinson and Company compare | 3.89% |
| COO The Cooper Companies, Inc. compare | 3.17% |
| ALC Alcon compare | 2.38% |
| RGEN Repligen Corporation compare | 2.18% |
| BAX Baxter International Inc. compare | −1.27% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on RMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement